CRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings Results, Misses Estimates By $0.06 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings results on Monday. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06), Briefing.com reports. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. The company’s revenue was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.98) earnings per share.

CRISPR Therapeutics Stock Down 2.8 %

NASDAQ:CRSP opened at $49.66 on Tuesday. The company has a fifty day moving average of $57.20 and a 200 day moving average of $63.27. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $91.10. The firm has a market capitalization of $4.22 billion, a P/E ratio of -18.26 and a beta of 1.70.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CRSP shares. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday. Needham & Company LLC lowered their price target on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday. Chardan Capital cut their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a research note on Friday. They set a “buy” rating and a $90.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $73.81.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.